01904nas a2200265   4500000000100000008004100001260003800042653001500080653001900095653002400114653001900138653001200157653002300169653002100192653001500213100001700228700002800245700002100273700002200294245009300316856022500409050002000634520097000654022001401624       2012                            d  c05/2012bElsevier EspañaaMadrid10aSmear test10aPaucibacillary10aMycobacteria leprae10aMultibacillary10aleprosy10aHansen’s disease10aFull text online10aDisability1 aEichelmann K1 aGonzález González S E1 aSalas-Alanis J C1 aOcampo-Candiani J00a[Leprosy. An Update: Definition, Pathogenesis, Classification, Diagnosis, and Treatment]  uhttp://apps.elsevier.es/watermark/ctl_servlet?_f=10&pident_articulo=15002&pident_usuario=0&pcontactid=&pident_revista=103&ty=125&accion=L&origen=elsevier&web=www.elsevier.es&lan=es&fichero=S0001-7310(12)00154-8.pdf&eop=1  aEICHELMANN 20123 a<p>Leprosy is a chronic granulomatous disease caused by the bacillus Mycobacterium leprae. It primarily affects the skin and peripheral nerves and is still endemic in various regions of the world. Clinical presentation depends on the patient's immune status at the time of infection and during the course of the disease. Leprosy is associated with disability and marginalization. Diagnosis is clinical and is made when the patient has at least 1 of the following cardinal signs specified by the World Health Organization: hypopigmented or erythematous macules with sensory loss; thickened peripheral nerves; or positive acid-fast skin smear or skin biopsy with loss of adnexa at affected sites. Leprosy is treated with a multidrug combination of rifampicin, clofazimine, and dapsone. Two main regimens are used depending on whether the patient has paucibacillary or multibacillary disease. Copyright © 2011 Elsevier España, S.L. y AEDV. All rights reserved.</p>
  a1578-2190